This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO 2019 - Grohé Poster

Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients following treatment with immune checkpoint inhibitors: updated results of the ongoing non-interventional study VARGADO (NCT02392455)

Grohé C, Gleiber W, Haas S, Krüger S, Schulze M, Atz J, Kaiser R​

 

ESMO 2019 VARGADO Grohe poster

Related articles

Learn more about the science behind this presentation in the papers and other materials below

Nintedanib* plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma

Grohé et al. Future Oncology 2019; DOI 10.2217/fon-2019-0262

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

Corral J et al. CTO 2019; DOI: 10.1007/s12094-019-02053-7

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: September 2019